Patents matching “therapy”

US 12420113

Methods and apparatus for applying tumor treating fields combined with personalized ultra-fractionated stereotactic adaptive radiotherapy

The Board of Regents of the University of Texas System · Granted Sep 23, 2025 · Expires Sep 18, 2045

US 12414983

CD200AR ligands for cancer immunotherapy

Regents of the University of Minnesota · Granted Sep 16, 2025 · Expires Sep 11, 2045

US 12404318

Combination HBV therapy

Vir Biotechnology, Inc. · Granted Sep 2, 2025 · Expires Aug 28, 2045

US 12397028

Adoptive cellular therapy

REGENERON PHARMACEUTICALS, INC. · Granted Aug 26, 2025 · Expires Aug 21, 2045

US 12397066

Delivery of gene therapy treatments

United States Government as represented by the Department of Veterans Affairs · Granted Aug 26, 2025 · Expires Aug 21, 2045

US 12385010

Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes

United States Government as represented by the Department of Veterans Affairs · Granted Aug 12, 2025 · Expires Aug 7, 2045

US 12384830

Compositions and methods for improving immunotherapy

Regents of the University of Minnesota · Granted Aug 12, 2025 · Expires Aug 7, 2045

US 12377093

Pyruvate kinase activators for use in therapy

Agios Pharmaceuticals, Inc. · Granted Aug 5, 2025 · Expires Jul 31, 2045

CN 120418289

Combination therapy of bispecific binding agents that bind to CLDN18.2 and CD3 with immune checkpoint inhibitors

ASTELLAS PHARMA EUROPE B V · Granted Aug 1, 2025 · Expires Jul 27, 2045

US 12370206

Therapy for inhibition of single-stranded RNA virus replication

RedHill Biopharma Ltd. · Granted Jul 29, 2025 · Expires Jul 24, 2045

US 12371747

Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy

BIOVERATIV THERAPEUTICS INC. · Granted Jul 29, 2025 · Expires Jul 24, 2045

US 12364765

Pegylated cystathionine beta synthase for enzyme therapy for treatment of homocystinuria

The Regents of the University of Colorado, a Body Corporate · Granted Jul 22, 2025 · Expires Jul 17, 2045

US 12364775

Viral vectors for cancer therapy

Krystal Biotech, Inc. · Granted Jul 22, 2025 · Expires Jul 17, 2045

US 12364774

Nucleic acid molecules and uses thereof for non-viral gene therapy

BIOVERATIV THERAPEUTICS INC. · Granted Jul 22, 2025 · Expires Jul 17, 2045

US 12359204

Soluble interleukin-7 receptor (SIL7R) modulating therapy to treat autoimmune diseases and cancer

The Board of Regents of the University of Texas System · Granted Jul 15, 2025 · Expires Jul 10, 2045

US 12350322

Peptide immunogens targeting interleukin 6 (IL-6) and formulations thereof for immunotherapy of diseases impacted by IL-6 dysregulation

United Biomedical, Inc. · Granted Jul 8, 2025 · Expires Jul 3, 2045

US 12350318

Combination therapy to treat brain cancer

REGENERON PHARMACEUTICALS, INC. · Granted Jul 8, 2025 · Expires Jul 3, 2045

US 12338450

Gene therapy constructs for treating Wilson disease

Ultragenyx Pharmaceutical Inc. · Granted Jun 24, 2025 · Expires Jun 19, 2045

US 12336976

Glutaminase inhibitor therapy

The Board of Regents of the University of Texas System · Granted Jun 24, 2025 · Expires Jun 19, 2045

US 12338459

DNA-chimeric antigen receptor T cells for immunotherapy

ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Jun 24, 2025 · Expires Jun 19, 2045

US 12337017

Microbiota transfer therapy for Pitt Hopkins Syndrome

ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Jun 24, 2025 · Expires Jun 19, 2045

US 12329816

Immunotherapy with metabolic enzyme expression

THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Jun 17, 2025 · Expires Jun 12, 2045

US 12329756

Regulation of eIF4E activity for migraine therapy

The Board of Regents of the University of Texas System · Granted Jun 17, 2025 · Expires Jun 12, 2045

US 12325854

Crispr-CPF1-related methods, compositions and components for cancer immunotherapy

Editas Medicine, Inc. · Granted Jun 10, 2025 · Expires Jun 5, 2045